Opinion

Video

Bladder Cancer: Treatment Options and Managing Adverse Effects

Author(s):

Axel Merseburger, MD, PhDM. Carmen Mir, MD, PhD

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Related Videos
A panel of 3 experts on CLL
A panel of 3 experts on CLL
Brian I. Rini, MD, FASCO
2 KOLs are featured in this program.
2 KOLs are featured in this program.
2 KOLs are featured in this series
2 KOLs are featured in this series
2 KOLs are featured in this series
Marc Machaalani, MD
3 KOLs are featured in this series.
Related Content
Brian Rini, MD, of Vanderbilt Cancer Center
July 21st 2024

KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Toni Choueiri, MD
July 18th 2024

Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition

Jack Khouri, MD
November 9th 2023

Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

Andrea B. Apolo, MD, of the National Institutes of Health
July 15th 2024

Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies

Aaron Gerds, MD, assistant professor, medicine, Hematology, and Medical Oncology, Cleveland Clinic Taussig Cancer Institute
July 15th 2024

Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials